ReP USP - Resultado da busca

Artigo de periodico
Therapeutic target attainment of 3-Hour extended Infusion of Meropenem in patients with septic burns (2022)
Messiano, Claudia Garcia; Morales Júnior, Ronaldo ; Pereira, Gabriela Otofuji; Silva Junior, Elson Mendes da; Gomez, David de Souza; Santos, Silvia Regina Cavani Jorge
Fonte: Clinical Therapeutics. Unidades: FCF, FM
Assuntos: QUEIMADURAS, FARMACODINÂMICA, FARMACOCINÉTICA, SEPSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MESSIANO, Claudia Garcia et al. Therapeutic target attainment of 3-Hour extended Infusion of Meropenem in patients with septic burns. Clinical Therapeutics, v. 44, p. 624-629, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.clinthera.2022.02.007. Acesso em: 29 jun. 2025.
APA
Messiano, C. G., Morales Júnior, R., Pereira, G. O., Silva Junior, E. M. da, Gomez, D. de S., & Santos, S. R. C. J. (2022). Therapeutic target attainment of 3-Hour extended Infusion of Meropenem in patients with septic burns. Clinical Therapeutics, 44, 624-629. doi:10.1016/j.clinthera.2022.02.007
NLM
Messiano CG, Morales Júnior R, Pereira GO, Silva Junior EM da, Gomez D de S, Santos SRCJ. Therapeutic target attainment of 3-Hour extended Infusion of Meropenem in patients with septic burns [Internet]. Clinical Therapeutics. 2022 ; 44 624-629.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2022.02.007
Vancouver
Messiano CG, Morales Júnior R, Pereira GO, Silva Junior EM da, Gomez D de S, Santos SRCJ. Therapeutic target attainment of 3-Hour extended Infusion of Meropenem in patients with septic burns [Internet]. Clinical Therapeutics. 2022 ; 44 624-629.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2022.02.007
Artigo de periodico
Fixed-combination bimatoprost/brimonidine/timolol in glaucom: a randomized, masked, controlled, phase III study conducted in Brazil (2020)
Belfort Junior, Rubens; Paula, Jayter Silva ; Silva, Marcelo Jordão Lopes; Della Paolera, Mauricio; Kim, Thomas; Chen, Michelle Y.; Goodkin, Margot L.
Fonte: Clinical Therapeutics. Unidade: FMRP
Assuntos: GLAUCOMA, HIPERTENSÃO OCULAR, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BELFORT JUNIOR, Rubens et al. Fixed-combination bimatoprost/brimonidine/timolol in glaucom: a randomized, masked, controlled, phase III study conducted in Brazil. Clinical Therapeutics, v. 42, n. 2, p. 263-275, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.clinthera.2019.12.008. Acesso em: 29 jun. 2025.
APA
Belfort Junior, R., Paula, J. S., Silva, M. J. L., Della Paolera, M., Kim, T., Chen, M. Y., & Goodkin, M. L. (2020). Fixed-combination bimatoprost/brimonidine/timolol in glaucom: a randomized, masked, controlled, phase III study conducted in Brazil. Clinical Therapeutics, 42( 2), 263-275. doi:10.1016/j.clinthera.2019.12.008
NLM
Belfort Junior R, Paula JS, Silva MJL, Della Paolera M, Kim T, Chen MY, Goodkin ML. Fixed-combination bimatoprost/brimonidine/timolol in glaucom: a randomized, masked, controlled, phase III study conducted in Brazil [Internet]. Clinical Therapeutics. 2020 ; 42( 2): 263-275.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2019.12.008
Vancouver
Belfort Junior R, Paula JS, Silva MJL, Della Paolera M, Kim T, Chen MY, Goodkin ML. Fixed-combination bimatoprost/brimonidine/timolol in glaucom: a randomized, masked, controlled, phase III study conducted in Brazil [Internet]. Clinical Therapeutics. 2020 ; 42( 2): 263-275.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2019.12.008
Artigo de periodico
Pharmacokinetic and pharmacodynamic characteristics of vancomycin and meropenem in critically Ill patients receiving sustained lowefficiency dialysis (2020)
Oliveira, Maura Salaroli de; Machado, Anna Silva; Mendes, Elisa Teixeira; Chaves, Lucas; Perdigão Neto, Lauro Vieira; Silva Junior, Carlindo Vieira da; Santos, Silvia Regina Cavani Jorge ; Sanches, Cristina; Macedo, Etienne; Levin, Anna Sara Shafferman
Fonte: Clinical Therapeutics. Unidades: FCF, FM
Assuntos: FARMACOCINÉTICA, FARMACODINÂMICA, PLASMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Maura Salaroli de et al. Pharmacokinetic and pharmacodynamic characteristics of vancomycin and meropenem in critically Ill patients receiving sustained lowefficiency dialysis. Clinical Therapeutics, v. 42, p. N. 4 625-633, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.clinthera.2020.02.011. Acesso em: 29 jun. 2025.
APA
Oliveira, M. S. de, Machado, A. S., Mendes, E. T., Chaves, L., Perdigão Neto, L. V., Silva Junior, C. V. da, et al. (2020). Pharmacokinetic and pharmacodynamic characteristics of vancomycin and meropenem in critically Ill patients receiving sustained lowefficiency dialysis. Clinical Therapeutics, 42, N. 4 625-633. doi:10.1016/j.clinthera.2020.02.011
NLM
Oliveira MS de, Machado AS, Mendes ET, Chaves L, Perdigão Neto LV, Silva Junior CV da, Santos SRCJ, Sanches C, Macedo E, Levin ASS. Pharmacokinetic and pharmacodynamic characteristics of vancomycin and meropenem in critically Ill patients receiving sustained lowefficiency dialysis [Internet]. Clinical Therapeutics. 2020 ; 42 N. 4 625-633.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2020.02.011
Vancouver
Oliveira MS de, Machado AS, Mendes ET, Chaves L, Perdigão Neto LV, Silva Junior CV da, Santos SRCJ, Sanches C, Macedo E, Levin ASS. Pharmacokinetic and pharmacodynamic characteristics of vancomycin and meropenem in critically Ill patients receiving sustained lowefficiency dialysis [Internet]. Clinical Therapeutics. 2020 ; 42 N. 4 625-633.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2020.02.011
Artigo de periodico
Harmonization of pharmacovigilance regulation in Brazil: opportunities to improve risk communication (2019)
Varallo, Fabiana Rossi ; Forgerini, Marcela ; Herdeiro, Maria Teresa Ferreira ; Mastroianni, Patricia de Carvalho
Fonte: Clinical Therapeutics. Unidade: FCFRP
Assuntos: SEGURANÇA DO PACIENTE, FÁRMACOS, FARMACOVIGILÂNCIA, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VARALLO, Fabiana Rossi et al. Harmonization of pharmacovigilance regulation in Brazil: opportunities to improve risk communication. Clinical Therapeutics, v. 41, n. 3, p. 598-603, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.clinthera.2019.01.013. Acesso em: 29 jun. 2025.
APA
Varallo, F. R., Forgerini, M., Herdeiro, M. T. F., & Mastroianni, P. de C. (2019). Harmonization of pharmacovigilance regulation in Brazil: opportunities to improve risk communication. Clinical Therapeutics, 41( 3), 598-603. doi:10.1016/j.clinthera.2019.01.013
NLM
Varallo FR, Forgerini M, Herdeiro MTF, Mastroianni P de C. Harmonization of pharmacovigilance regulation in Brazil: opportunities to improve risk communication [Internet]. Clinical Therapeutics. 2019 ; 41( 3): 598-603.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2019.01.013
Vancouver
Varallo FR, Forgerini M, Herdeiro MTF, Mastroianni P de C. Harmonization of pharmacovigilance regulation in Brazil: opportunities to improve risk communication [Internet]. Clinical Therapeutics. 2019 ; 41( 3): 598-603.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2019.01.013
Artigo de periodico
Clinical outcome and antimicrobial therapeutic drug monitoring for the treatment of infections in acute burn patients (2017)
Machado, Anna Silva; Oliveira, Maura S; Sanches, Cristina; Silva Junior, Carlindo Vieira da; Gomez, David S; Gemperli, Rolf; Santos, Silvia Regina Cavani Jorge ; Levin, Anna Sara Shafferman
Fonte: Clinical Therapeutics. Unidades: FCF, FM
Assuntos: ANTIBIÓTICOS, DOENÇAS INFECCIOSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO, Anna Silva et al. Clinical outcome and antimicrobial therapeutic drug monitoring for the treatment of infections in acute burn patients. Clinical Therapeutics, v. 39, n. 8, p. 1649-1657, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.clinthera.2017.06.008. Acesso em: 29 jun. 2025.
APA
Machado, A. S., Oliveira, M. S., Sanches, C., Silva Junior, C. V. da, Gomez, D. S., Gemperli, R., et al. (2017). Clinical outcome and antimicrobial therapeutic drug monitoring for the treatment of infections in acute burn patients. Clinical Therapeutics, 39( 8), 1649-1657. doi:10.1016/j.clinthera.2017.06.008
NLM
Machado AS, Oliveira MS, Sanches C, Silva Junior CV da, Gomez DS, Gemperli R, Santos SRCJ, Levin ASS. Clinical outcome and antimicrobial therapeutic drug monitoring for the treatment of infections in acute burn patients [Internet]. Clinical Therapeutics. 2017 ; 39( 8): 1649-1657.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2017.06.008
Vancouver
Machado AS, Oliveira MS, Sanches C, Silva Junior CV da, Gomez DS, Gemperli R, Santos SRCJ, Levin ASS. Clinical outcome and antimicrobial therapeutic drug monitoring for the treatment of infections in acute burn patients [Internet]. Clinical Therapeutics. 2017 ; 39( 8): 1649-1657.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2017.06.008
Trabalho de evento-resumo periodico
Influence of verapamil on the pharmacokinetics of oxcarbazepine and 10-hydroxycarbazepine enantiomers in healthy volunteers (2013)
Antunes, Natalícia de Jesus; Wichert-Ana, Lauro; Coelho, Eduardo Barbosa; Pasqua, O. Della; Alexandre Júnior, V; Takayanagui, Osvaldo Massaiti; Lanchote, Vera Lúcia
Fonte: Clinical Therapeutics. Nome do evento: Conference of the European Association for Clinical Pharmacology and Therapeutics (EACPT). Unidades: FMRP, FCFRP
Assuntos: FARMACOCINÉTICA, FARMACOLOGIA, CONVULSÕES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ANTUNES, Natalícia de Jesus et al. Influence of verapamil on the pharmacokinetics of oxcarbazepine and 10-hydroxycarbazepine enantiomers in healthy volunteers. Clinical Therapeutics. Bridgewater: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 29 jun. 2025. , 2013
APA
Antunes, N. de J., Wichert-Ana, L., Coelho, E. B., Pasqua, O. D., Alexandre Júnior, V., Takayanagui, O. M., & Lanchote, V. L. (2013). Influence of verapamil on the pharmacokinetics of oxcarbazepine and 10-hydroxycarbazepine enantiomers in healthy volunteers. Clinical Therapeutics. Bridgewater: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo.
NLM
Antunes N de J, Wichert-Ana L, Coelho EB, Pasqua OD, Alexandre Júnior V, Takayanagui OM, Lanchote VL. Influence of verapamil on the pharmacokinetics of oxcarbazepine and 10-hydroxycarbazepine enantiomers in healthy volunteers. Clinical Therapeutics. 2013 ; 35( 85): e76.[citado 2025 jun. 29 ]
Vancouver
Antunes N de J, Wichert-Ana L, Coelho EB, Pasqua OD, Alexandre Júnior V, Takayanagui OM, Lanchote VL. Influence of verapamil on the pharmacokinetics of oxcarbazepine and 10-hydroxycarbazepine enantiomers in healthy volunteers. Clinical Therapeutics. 2013 ; 35( 85): e76.[citado 2025 jun. 29 ]
Artigo de periodico
Bioequivalence evaluation of single doses of two tramadol formulations: a randomized, open-label, two-period crossover study in healthy Brazilian volunteers (2010)
Silva, Marina de Freitas; Schramm, Simone Grigoleto; Kano, Eunice Kazue; Koono, Eunice Emiko Mori; Porta, Valentina ; Serra, Cristina Helena dos Reis
Fonte: Clinical Therapeutics. Unidade: FCF
Assuntos: BIOEQUIVALÊNCIA, FARMACOCINÉTICA, CROMATOGRAFIA LÍQUIDA DE ALTA EFICIÊNCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Marina de Freitas et al. Bioequivalence evaluation of single doses of two tramadol formulations: a randomized, open-label, two-period crossover study in healthy Brazilian volunteers. Clinical Therapeutics, v. 32, n. 4, p. 758-765, 2010Tradução . . Disponível em: http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6VRS-4YYPPM6-H-1&_cdi=6242&_user=5674931&_pii=S0149291810001074&_orig=browse&_coverDate=04%2F30%2F2010&_sk=999679995&view=c&wchp=dGLzVzz-zSkzS&md5=39b0f577aa141d4e2b40edd118fdd7a3&ie=/sdarticle.pdf. Acesso em: 29 jun. 2025.
APA
Silva, M. de F., Schramm, S. G., Kano, E. K., Koono, E. E. M., Porta, V., & Serra, C. H. dos R. (2010). Bioequivalence evaluation of single doses of two tramadol formulations: a randomized, open-label, two-period crossover study in healthy Brazilian volunteers. Clinical Therapeutics, 32( 4), 758-765. Recuperado de http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6VRS-4YYPPM6-H-1&_cdi=6242&_user=5674931&_pii=S0149291810001074&_orig=browse&_coverDate=04%2F30%2F2010&_sk=999679995&view=c&wchp=dGLzVzz-zSkzS&md5=39b0f577aa141d4e2b40edd118fdd7a3&ie=/sdarticle.pdf
NLM
Silva M de F, Schramm SG, Kano EK, Koono EEM, Porta V, Serra CH dos R. Bioequivalence evaluation of single doses of two tramadol formulations: a randomized, open-label, two-period crossover study in healthy Brazilian volunteers [Internet]. Clinical Therapeutics. 2010 ; 32( 4): 758-765.[citado 2025 jun. 29 ] Available from: http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6VRS-4YYPPM6-H-1&_cdi=6242&_user=5674931&_pii=S0149291810001074&_orig=browse&_coverDate=04%2F30%2F2010&_sk=999679995&view=c&wchp=dGLzVzz-zSkzS&md5=39b0f577aa141d4e2b40edd118fdd7a3&ie=/sdarticle.pdf
Vancouver
Silva M de F, Schramm SG, Kano EK, Koono EEM, Porta V, Serra CH dos R. Bioequivalence evaluation of single doses of two tramadol formulations: a randomized, open-label, two-period crossover study in healthy Brazilian volunteers [Internet]. Clinical Therapeutics. 2010 ; 32( 4): 758-765.[citado 2025 jun. 29 ] Available from: http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6VRS-4YYPPM6-H-1&_cdi=6242&_user=5674931&_pii=S0149291810001074&_orig=browse&_coverDate=04%2F30%2F2010&_sk=999679995&view=c&wchp=dGLzVzz-zSkzS&md5=39b0f577aa141d4e2b40edd118fdd7a3&ie=/sdarticle.pdf
Artigo de periodico
Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study (2008)
Serra, Cristina Helena dos Reis ; Koono, Eunice Emiko Mori; Kano, Eunice Kazue; Schramm, Simone Grigoleto; Armando, Yara Popst; Porta, Valentina
Fonte: Clinical Therapeutics. Unidade: FCF
Assuntos: BIOEQUIVALÊNCIA, ZIDOVUDINA (FARMACOCINÉTICA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SERRA, Cristina Helena dos Reis et al. Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study. Clinical Therapeutics, v. 30, n. 5, p. 902-908, 2008Tradução . . Disponível em: https://doi.org/10.1016/j.clinthera.2008.05.003. Acesso em: 29 jun. 2025.
APA
Serra, C. H. dos R., Koono, E. E. M., Kano, E. K., Schramm, S. G., Armando, Y. P., & Porta, V. (2008). Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study. Clinical Therapeutics, 30( 5), 902-908. doi:10.1016/j.clinthera.2008.05.003
NLM
Serra CH dos R, Koono EEM, Kano EK, Schramm SG, Armando YP, Porta V. Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study [Internet]. Clinical Therapeutics. 2008 ;30( 5): 902-908.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2008.05.003
Vancouver
Serra CH dos R, Koono EEM, Kano EK, Schramm SG, Armando YP, Porta V. Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study [Internet]. Clinical Therapeutics. 2008 ;30( 5): 902-908.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2008.05.003

Unidades USP

ReP

Filtros

Departamento

Autores

Autores USP

Ano de publicação

Assuntos

Indexado em

Afiliação dos autores externos não normalizada